Medera Inc., a clinical-stage biopharmaceutical company developing treatments for cardiovascular diseases, has reached an agreement to go public on the Nasdaq through a merger with Keen Vision Acquisition Corp. (Nasdaq: KVAC).
To read the entire story, you must be logged in.
Please log in now or register with us.
